REMARKS

This amendment is submitted to cancel claims in order to reduce the filing fee and to place the claims in a condition suitable for U.S. Patent Practice by deleting phrases beginning with the term "preferably". There is no new matter added, and entry of the amendment is respectfully requested.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: January 25, 2002

Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

Attorney Docket No.: 10127.200-US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Peter Paasch Mortensen — Serial No.: To be assigned

Confirmation No: To be assigned — Group Art Unit: To be assigned

Filed: January 25, 2002 — Examiner: To be assigned

For: Method of Analyzing Granular Composition by Fluorescence Analysis

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Sir:

Below is a marked-up version of the amendments made in the accompanying amendment.

IN THE CLAIMS:

Claims 4-6, 17,19-20, 44 have been amended as follows:

4. (Amended.) The method of claim 3, wherein the ultraviolet light consist of one discrete monochromatic wavelength[, particularly between 260-280 nm].

5. (Amended.) The method of claim 1, wherein the detecting of light emitted from the fluorescent marker consists of detecting emitted light of 1-10 discrete monochromatic wavelengths[, particularly between 185-2600 nm].

6. (Amended.) The method of claim 5, wherein the fluorescent marker is the biologically active compound and the detecting of light emitted from the fluorescent marker consists of detecting emitted light of one discrete monochromatic wavelength[, particularly between 300-400 nm].

17. (Amended.) The method of claim 16, wherein the fluorescent marker is an auxiliary granulation agent and the detecting of light emitted from the fluorescent marker consists of detecting emitted light of one discrete monochromatic wavelength[, particularly between 350-500 nm].

19. (Amended.) The method of claim 1, wherein the granules comprise a core particle coated with a layer comprising the biologically active compound [and particularly auxiliary granulation agents].

20. (Amended.) The method of claim 1, wherein the granules have an average size between 20-2000 μm[, particularly between 100-1000 μm, more particularly between 200-800 μm].

44. (Amended.) A method for determining the quality parameter of an unknown granular composition, comprising the steps of:

a) providing a calibration model by illuminating a granular composition comprising a purified biologically active compound having a known quality parameter with light capable of fluorescence excitation of a fluorescent marker comprised in the granular composition, recording one or more images of the light emitted from the granular composition of a known quality and subjecting recorded images to data processing[, particularly in the form of partial least squares data processing,] to form a calibration model,

b) illuminating a unknown granular composition comprising a purified biologically active compound with light capable of fluorescence excitation of a fluorescent marker comprised in the granular composition, recording at least one image of the light emitted from the unknown granular composition,

c) comparing at least one image of the unknown granular composition with the calibration model and

d) estimating the quality parameter of the unknown granular composition.